Automotive dealer Anil Garg of Shiva Auto passes away
New Delhi:
Anil Garg
, the founder of the Noida and NCR-based dealership conglomerate
Shiva Auto
Group, passed away on Tuesday morning.
Garg began his entrepreneurial journey in 1972 with an authorised service and spare parts dealership for
Bajaj Auto
in Ghaziabad. In 1987, he expanded the venture as an authorised sales dealer for Bajaj, laying the foundation for what would grow into a diversified automotive group.
Growing along with Bajaj, in 1995 Shiva Group was appointed as the C&F genuine spares for Uttar Pradesh region.
Over the decades, Garg guided the business through significant milestones, including securing the General Motors dealership in 2004 and the Mahindra dealership in 2009.
A Mechanical Engineer by qualification, he brought over 41 years of deep industry insight and operational excellence to his ventures. Known for his steadfast commitment to customer satisfaction and a leadership style, he earned widespread respect across the industry.
His legacy continues through his son, Amit Garg, who joined the business in 1997 and currently serves as Director of the Group. Under Amit's leadership, the Shiva Auto Group expanded its portfolio to include brands such as
Jaguar Land Rover (JLR)
,
Triumph
and
KTM
bikes,
Bajaj Chetak
scooters, and
Bajaj three-wheelers
.
'I had the good fortune of knowing him for over three decades. His humility and customer orientation were legendary– qualities that are sharply etched in my memory,' said auto industry veteran Arun Malhotra.
Industry veterans say Garg's contributions to the auto dealership ecosystem leave a lasting imprint, both through the scale of his enterprise and the values he instilled in it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
13 minutes ago
- India Today
Come to office or leave: Google gets tough on work-from-office policy, starts offering voluntary exits
Google has taken a tougher approach towards remote work in the US, asking more employees to return to the office or opt for a voluntary exit package. The company has rolled out a new return-to-office (RTO) rule for teams working in key areas like Core, Marketing, Research, Knowledge & Information (K&I), and Communications. The K&I group includes employees involved in major products such as Google Search, commerce and part of this move, employees who have been working remotely but live within 50 miles of a Google office are being told to switch to a hybrid schedule. This means they must start coming to the office at least three days a week. While Google had already introduced a hybrid work policy in 2022, this new step expands its reach and makes the expectation go along with this, the company is offering a voluntary exit programme to certain US-based employees, according to the internal memo accessed by Business Insider. Those who choose to leave will get a severance package. A spokesperson for Google said this option is being provided to help the company focus on the work ahead, and it's already been tried in other teams with positive The memo, which is shared by a top Google executive, explained that the company is in the middle of an important change, especially with the rise of AI. To keep up with the pace of change, Google wants its teams to be more connected and collaborative, something it believes happens better with in-person voluntary exit is also being positioned as a chance for people who feel less connected to the company's goals to step away, while creating room for others to grow within the organisation. Google has clarified that this is not a round of layoffs, but a way to bring more focus and energy to important the announcement has raised some concerns. In the past, Google has followed similar exit offers with job cuts. In 2023, the company let go of around 12,000 employees globally, and this year too, it carried out smaller rounds of layoffs in teams like Treasury and Business it is not clear how many people will be impacted this time, the message is clear. Google wants more of its staff back in office, and those who are not willing may have the option to walk away.
India Today
14 minutes ago
- India Today
Hero Honda CD 100: Hero's stepping stone to becoming the largest two-wheeler maker
Launched in 1983, this bike didn't just ride onto Indian roads—it rolled into the hearts of millions, becoming a symbol of reliability, efficiency, and the dreams of a nation finding its 1980s were a different era for India. The roads buzzed with two-stroke icons like the Yamaha RX 100, Kawasaki Bajaj RTZ, Yamaha RD 350, and the quirky Yezdi. For the family man, the Bajaj scooter was the go-to choice. advertisementThen came the Hero Honda CD 100, a motorcycle that dared to be different. Its design was understated—chromed mudguards, a rectangular headlamp, a basic instrument panel, and a spacious seat. It wasn't built to dazzle but to deliver. Powered by a 96cc four-stroke engine, producing 7.5bhp and 7.2Nm of torque, and paired with a four-speed gearbox, the CD 100 prioritised practicality. Its top speed of 80kmph couldn't match the two-stroke speedsters, but its trump card was excellent fuel efficiency of 80 kmpl—a figure that felt like wizardry in its time. Hero Honda struck gold with a marketing masterstroke. The tagline 'Fill it, shut it, forget it' captured the bike's promise of carefree, fuel-sipping rides. It was extremely fuel-efficient, which is what set it apart from the two-stroke bikes available on the market. Add to that the star power of Bollywood's Salman Khan, and the CD 100 became an overnight sensation. Its four-stroke engine and unmatched reliability set it apart from its two-stroke rivals, which often grappled with fuel overflow and frequent maintenance. For the average Indian, the CD 100 was a revelation—a bike that started every morning and kept going without fuss. advertisement The CD 100 was more than a mode of transport; it was a companion for life's journeys. It carried families to markets, students to schools, and workers to their livelihoods. Its legacy lived on through successors like the CD 100SS, Hero Honda Sleek, and the evergreen Hero Honda Splendor, which remains a staple on Indian roads. Even now, the CD 100 sparks nostalgia across generations. As Hero MotoCorp forges ahead with modern marvels, the CD 100 stands as a testament to its beginnings—a simple bike that fueled India's dreams and redefined what a motorcycle could be. Long live the Hero Honda CD 100, an icon that still rides strong in to Auto Today Magazine
Business Standard
35 minutes ago
- Business Standard
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.
